Philip Wood

The Bracton Centre, Oxleas NHS Trust, Дартфорде, England, United Kingdom

Are you Philip Wood?

Claim your profile

Publications (5)20.45 Total impact

  • P Wood, D Peckham
    Praxis 03/2010; 99(6):373-6.
  • P. Wood, D. Peckham
    Schweizerische Rundschau Fur Medizin Praxis - SCHWEIZ RUNDSCH MED PRAX. 01/2010; 099(06):373-376.
  • Philip Wood
    [Show abstract] [Hide abstract]
    ABSTRACT: The primary antibody deficiency syndromes are a rare group of immunodeficiencies where diagnostic delay remains common due to limited awareness of the existence and heterogeneity of their presenting features. Referral for specialist assessment leads to earlier diagnosis and appropriate therapy to prevent or limit structural organ and tissue damage. Greater education of healthcare professionals is required to ensure prompt recognition and referral to specialists with expertise in the care of primary immunodeficiencies, especially since study of these rare conditions is a minor part of undergraduate and general postgraduate training. Greater awareness would lead to reduced morbidity, improved quality of life and survival outcomes in this patient group.
    Clinical medicine (London, England) 12/2009; 9(6):595-9. · 1.32 Impact Factor
  • P Wood
    [Show abstract] [Hide abstract]
    ABSTRACT: The primary antibody deficiency syndromes are a group of rare disorders characterized by an inability to produce clinically effective immunoglobulin responses. Some of these disorders result from genetic mutations in genes involved in B cell development, whereas others appear to be complex polygenic disorders. They most commonly present with recurrent infections due to encapsulated bacteria, although in the most common antibody deficiency, Common Variable Immunodeficiency, systemic and organ-specific autoimmunity can be a presenting feature. Diagnostic delay in this group of disorders remains a problem, and the laboratory has a vital role in the detection of abnormalities in immunoglobulin concentration and function. It is critical to distinguish this group of disorders from secondary causes of hypogammaglobulinaemia, in particular lymphoid malignancy, and appropriate laboratory investigations are of critical importance. Treatment of primary antibody deficiencies involves immunoglobulin replacement therapy, either via the intravenous or subcutaneous route. Patients remain at risk of a wide variety of complications, not all linked to diagnostic delay and inadequate therapy. In common variable immunodeficiency (CVID) in particular, patients remain at significantly increased risk of lymphoid malignancy, and regular clinical and laboratory monitoring is required. This review aims to give an overview of these conditions for the general reader, covering pathogenesis, clinical presentation, laboratory investigation, therapy and clinical management.
    Annals of Clinical Biochemistry 02/2009; 46(Pt 2):99-108. · 1.92 Impact Factor
  • Philip Wood, Daniel Peckham
    BMJ (online) 01/2009; 339:b4118. · 17.22 Impact Factor

Publication Stats

26 Citations
20.45 Total Impact Points

Institutions

  • 2009–2010
    • The Bracton Centre, Oxleas NHS Trust
      Дартфорде, England, United Kingdom
    • Nottinghamshire Healthcare NHS Trust
      Nottigham, England, United Kingdom